Primosiston Tablets

Quick links to important sections

Primosiston Tablets

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Primosiston Tablets

Quick Facts

Property Description
Active ingredients Ethinyl Estradiol, Norethindrone
Form Oral Tablets
Pharmacological class Combination Estrogen and Progestin
General purpose Hormonal cycle stabilization
Origin Synthetic Hormones

What Type of Medicine is Primosiston Tablets?

Primosiston Tablets is a Combined Sex-Hormonal Preparation classified as a Combination Estrogen and Progestin medicine used for Systemic Use. This medication is an oral tablet belonging to a pharmacological group dedicated to regulating the female reproductive system. The combination of its active ingredients is a standard therapeutic approach for hormonal control, and the formulation is established for modulating cyclical events in the body. Primosiston is clinically recognized for its effectiveness in providing structured hormonal regulation, distinguishing it as a specific, pre-determined regimen within the broader class of Combination Estrogen and Progestin products, making it suitable for defined courses of therapy.


Composition, Origin, and General Therapeutic Role

The active ingredients are synthetic derivatives engineered for specific oral potency: Ethinyl Estradiol (the synthetic estrogen component) and Norethindrone (a synthetic progestin, also known as Norethisterone). The medication's Dosage form is Oral Tablets, which delivers the combination of these two hormonal components into the body for Systemic Use. Its established classification confirms its ability to influence the timing and nature of menstrual events. The general therapeutic purpose of this Combination Medicine is to provide a powerful dual influence on the female reproductive system. This is frequently utilized to manage and stabilize conditions in Women of Reproductive Age where abnormal bleeding patterns or the need for cycle manipulation are key concerns.

Regulatory References

  1. Ethinyl Estradiol and Norethindrone Drug Information

What side effects are possible with Primosiston Tablets?

Possible Side Effects and Safety Information

The safety profile of Primosiston Tablets (Ethinyl Estradiol/Norethindrone) is established through official regulatory documentation, classifying potential adverse reactions by both frequency and the body system affected. These classifications reflect how government authorities organize and communicate the medicine's risks.

Adverse reactions are grouped across several System-Organ Classes (SOCs), including the Vascular System, Nervous System, and Hepatobiliary System.

Frequency-Classified Adverse Reactions

Classification Examples of Officially Documented Adverse Reactions
Common Nausea, Vomiting, Headache, Abdominal Pain, Breast Tenderness, Mood Swings/Disturbance, Weight Fluctuation.
Uncommon Increased Blood Pressure, Migraine, Fluid Retention.

The regulatory label highlights the potential for Serious Adverse Reactions, which are generally classified as rare. The most significant documented risks include Venous and Arterial Thromboembolism (blood clots, including Deep Vein Thrombosis, Pulmonary Embolism, Myocardial Infarction, and Stroke) and the very rare association with Benign or Malignant Liver Tumours (Hepatic Neoplasia).

Population-Specific and Time-Related Safety Patterns

The official documentation includes specific safety constraints. A significantly increased risk of serious cardiovascular events is noted for smokers over 35 years of age. Use is contraindicated in individuals with a history of thromboembolic disorders or severe chronic liver disease.

Additionally, the risk of Venous Thromboembolism is documented to be highest during the first year of use. Breakthrough bleeding or spotting is often noted, particularly during the initial three months of treatment, which typically resolves as use continues.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documentation for hormonal combination products, including those containing Ethinyl Estradiol and Norethindrone, states that acute overdose is associated with a low acute toxicity profile. Serious adverse effects are generally not reported following the ingestion of large doses, including in populations such as young children.

Documented Overdose Manifestations

Symptoms that may occur following an overdose are consistent with the hormonal components and primarily include nausea and vomiting. Other documented clinical signs are breast enlargement or tenderness, often followed by vaginal bleeding (withdrawal bleeding) after the ingestion is stopped.

Required Emergency Actions

Seek immediate medical attention for assessment and management in the event of a suspected overdose. Treatment is strictly symptomatic and supportive, as no specific antidote is known for this combination. A healthcare professional may consider gastric lavage if the quantity of the overdosage is large and is addressed within the first few hours following ingestion, underscoring the need for urgent medical contact.

Therapeutic Uses of Primosiston Tablets

What Primosiston Tablets Treats: Main Uses and Benefits

The medication is applied across domains where additional symptomatic support is needed for gynecological symptoms and is relevant for easing symptoms associated with temporary cycle planning. Its hormonal components are generally used to address symptom clusters that may become intense or disruptive in women of reproductive age.

It is applied for addressing abnormal uterine bleeding, such as severe or unscheduled bleeding patterns, and is relevant for easing symptoms associated with temporary cycle planning, particularly in clinical settings that involve temporary symptom management related to cycle timing. This therapy is commonly used to help with acute episodes of excessive blood loss and is applied in situations involving recurrent or episodic manifestations of bleeding patterns.

This medication is considered relevant in contexts where short-term symptomatic assistance is needed for symptoms that create noticeable physiological strain related to the menstrual cycle.

By providing hormonal support, the therapy assists with maintaining functional stability during acute phases and helps to maintain a sense of stability when symptoms are more noticeable, contributing to improved comfort during symptomatic periods.


Quick Fact: Support for Symptoms of Excessive Bleeding

Regulatory References

  1. NIH MedlinePlus Drug Information overview

Eligibility and Restrictions for Use

Who Can and Cannot Use Primosiston Tablets?

Eligibility for Primosiston Tablets (a high-dose hormonal medication containing Norethisterone and often Ethinylestradiol) is strictly regulated, primarily based on ruling out serious cardiovascular and hormonal risks. Its use is limited to women of reproductive potential who do not have any contraindications.


Absolute Contraindications (Must Not Use)

Condition / Population Status
Current or History of Thrombosis (DVT, PE, Stroke, Heart Attack) Prohibited
Severe Liver Disease or Liver Tumours (Benign or Malignant) Prohibited
Known or Suspected Pregnancy or Lactation Prohibited
Sex Hormone-Dependent Malignancies (Known or Suspected) Prohibited
Undiagnosed Genital Bleeding Prohibited

Populations Requiring Strict Medical Supervision

Use requires special care or close monitoring for patients with conditions potentially aggravated by fluid retention, such as epilepsy, asthma, or mild cardiac/renal dysfunction. Patients with Diabetes Mellitus also require strict supervision. The use of this medicine is not established in older adults or children.

What should I know about interactions with other medicines?

Primosiston Tablets Interactions with other medicines and products

The interaction profile of Primosiston Tablets, which contains Ethinyl Estradiol and Norethindrone, is defined by specific drug classes and substances that may alter the hormone concentrations in the body or increase established risks. This information is based on official government regulatory documents.


Formally Contraindicated Combinations

Co-administration with specific Hepatitis C drug combinations is formally prohibited. This includes medicinal products containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir, due to the potential for significant liver enzyme elevation.


Clinically Significant Interactions

These interactions primarily involve substances that affect hormone levels. Drugs that are strong CYP3A4 inducers, such as the antibiotic Rifampin or certain anticonvulsants (e.g., phenobarbital, phenytoin, carbamazepine), are documented to decrease the plasma concentrations of the active hormones, potentially reducing effectiveness.

Conversely, substances like Grapefruit or Grapefruit Juice are noted in regulatory information to potentially increase the concentration of the estrogen component.


Interaction-Related Restrictions and Cautions

Restriction Type Official Requirement
Surgical Procedures Discontinuation is required at least 4 weeks prior to and through 2 weeks after major surgery or prolonged immobilization.
Herbal Products St. John's Wort (Hypericum perforatum) is documented as a potent enzyme inducer that may significantly reduce hormone concentrations.
Population Note Plasma hormone concentrations may be increased in patients with renal impairment.

Mechanism of Action

How Primosiston Tablets Works

Primosiston's pharmacodynamic action is centered on its hormonal components, norethisterone (a progestin) and ethinylestradiol (an estrogen). These synthetic hormones exert their effects by functioning as agonists at the body’s progesterone and estrogen receptors (PRs and ERs).

This receptor-mediated signaling initiates a central negative feedback loop that modulates the hypothalamic-pituitary-ovarian (HPO) axis. The combined action suppresses the pulsatile release of Follicle-Stimulating Hormone (FSH) and Luteinizing Hormone (LH) from the pituitary gland, modifying the threshold for ovarian-pituitary communication.

At the peripheral level, the active ingredients induce direct morphological and secretory changes in the reproductive tract tissues. These alterations affect the endometrial lining, leading to decidualization and structural integrity changes. They also modify the properties of the cervical mucus, collectively influencing local tissue responses and systemic physiological regulation.

Dosage and Administration Information

How to Use Primosiston Tablets: Administration Guidelines

The usage of Primosiston Tablets is defined by prescribing information, outlining the specific administration method, dose frequency, and duration for gynecological cycle management. The medication is an oral dosage form and must be swallowed whole with some liquid, without regard to meals. To ensure consistent hormonal delivery, administration should occur at the same time every day.

Administration Scope

Feature Standard Administration Guidelines
Route of administration Oral use only.
Dosing schedule Dose is based on the specific regimen, often requiring one tablet, one to three times daily (BID or TID) as described in prescribing documents.
Timing May be administered without regard to meals; however, it must be taken at the same time every day.
Age-group rules Use is established for Women of Reproductive Age; the product is not for use in children.
Missed-dose rules If a dose is missed, only the last missed tablet should be taken as soon as remembered. Subsequent doses must be taken at the usual scheduled time; double doses are not permitted.

Course Duration and Frequency

Primosiston is designed for short-term and intermittent use, with duration limited by the treatment goal. For the arrest of acute dysfunctional bleeding, a course of approximately 10 days is typically prescribed. For prophylaxis or cycle postponement, the course duration is generally limited to 8 to 14 days. Use is structured as a cyclic or short-course regimen, requiring adherence to multiple daily dosing.

Recent Clinical Evidence

Research evidence / Overview of studies for Primosiston Tablets


Evidence for Use in Abnormal Uterine Bleeding (AUB)

Research on this hormonal combination was studied for conditions characterized by fluctuating or episodic manifestations, such as abnormal uterine bleeding (AUB). The evidence base includes randomized controlled trials (RCTs) and systematic reviews applied in research contexts involving fluctuating or unstable symptoms. Findings describe patterns observed in the studies related to acute bleeding episodes. Trials reported measurements of menstrual blood loss in the observed populations and tracked the time until bleeding cessation. Studies also monitored cycle regularity patterns during the treatment period.

However, certainty remains low regarding the sustained effect after the treatment period ends. Long-term effects are not fully established, meaning there is limited information on whether cycle stability patterns observed during treatment persist over time. Furthermore, comparative evidence is lacking to understand these findings in relation to other therapeutic options.


Studies on Excessive Blood Loss and Cycle Stabilization

Research examined the combination in conditions associated with acute or disruptive episodes, specifically focusing on outcomes related to physical discomfort and excessive menstrual blood loss (MBL). Data show patterns related to changes in the measured volume of menstrual blood loss compared to baseline assessments recorded before treatment began. Findings also indicate patterns related to cycle regularity and predictability in the studies. The research provides insight into short-term changes, helping to contextualize how patients reported their experience of acute and chronic heavy bleeding symptoms during the study period.

It is important to note that findings were mixed when considering the entire class of combined oral contraceptives (COCs) studied for MBL, and the specific high-dose formulation in this medication was not always the subject of the largest-scale contemporary comparative trials. Therefore, evidence quality varies across studies, and comparative evidence is limited when assessing this specific formulation against other regimens.


Research on Temporary Cycle Management and Postponement

This medication was also observed in research scenarios exploring short-term symptom changes, specifically the temporary delay of scheduled menstruation. Studies report how symptoms evolved in the observed populations, indicating postponement of menstruation correlating with the course of hormonal administration. However, research describes that some participants in the observed populations experienced patterns of unscheduled bleeding or spotting during the time the cycle was being postponed. Data are still emerging to fully characterize this application, and certainty remains low regarding the comparative outcome profiles when compared to other hormonal methods used for temporary cycle management.

Key Studies & References

  1. Heavy menstrual bleeding: assessment and management (NICE Guideline NG88)
  2. How to Delay a Period or How to Postpone Menstruation (Clinical Guidance Overview)
  3. NORELUT/NORETHINDRONE tablet (DailyMed/FDA - Norethindrone and Ethinyl Estradiol Labeling)

Frequently Asked Questions (FAQ)

Common questions about Primosiston Tablets (FAQ)


Q: Can Primosiston Tablets affect my ability to become pregnant later?

Regulatory information on combined hormonal medications indicates that after stopping the tablets, there may be a short-term delay in the return of a normal menstrual cycle and ovulation. For the majority of women, fertility patterns are generally expected to return to their previous state within a few months. Regulatory information indicates that the return to previous fertility patterns is generally not affected long-term.


Q: Can I take Primosiston Tablets if I am already taking an antibiotic?

The official drug interaction profile identifies specific antibiotics that are potent enzyme inducers, such as Rifampin, which can be of concern. These substances are documented to potentially decrease the concentration of the active ingredients in the blood, which could reduce the expected effect of the medication. Information regarding interacting medications should always be discussed with a healthcare provider.


Q: What if I experience unusual or severe pain while taking Primosiston Tablets?

The regulatory warnings describe certain serious or unusual symptoms that may require medical attention. These symptoms include the first signs of a possible blood clot, such as unusual pains or swelling in the legs, or the first occurrence of a migraine or unusually severe headaches. These symptoms are serious safety signals, and official guidance describes that medical attention is warranted if they occur.


Q: What is the difference between Primosiston Tablets and a typical birth control pill?

Primosiston is a combination hormonal product with specific high amounts of Ethinyl Estradiol and Norethisterone. Unlike combination oral contraceptives (COCs), which are regulated primarily for the prevention of pregnancy, Primosiston is regulated for specific short-course indications. These uses include the treatment of dysfunctional uterine bleeding and the temporary postponement of menstruation.


Q: Why is Primosiston Tablets typically only taken for a short period of time?

Regulatory documents define this medication for short-course and intermittent use, with duration typically limited to 8 to 14 days, depending on the prescribing goal. This prescribing structure is related to the medication’s high hormonal dose and established safety constraints. The short duration of use is a regulatory constraint implemented due to the potential for blood clots and other risks, which are best managed with limited exposure.


Q: What are the ingredients in Primosiston Tablets besides the main active component?

The tablet contains the active ingredients Ethinyl Estradiol and Norethisterone. The inactive ingredients, also known as excipients, are listed in the official composition documents. These typically include substances such as lactose, starch, povidone, talc, and magnesium stearate, which are used to form the tablet.


Q: Why do some people experience spotting while taking Primosiston Tablets?

Official regulatory documents note that unscheduled bleeding or spotting is a documented pattern that may occur while taking the tablets. This pattern is particularly seen during the early stages of treatment or when the medication is used for cycle postponement. This event is related to the hormonal action of the medication as it stabilizes the uterine lining.


Q: How quickly does Primosiston Tablets start working to affect bleeding?

According to regulatory information for its use in treating dysfunctional uterine bleeding, the medication is expected to arrest or suspend the bleeding quickly. This effect is typically observed within 1 to 3 days after starting the prescribed course of tablets.


Q: What happens to my period after I stop taking Primosiston Tablets?

After you have completed the prescribed course and stopped taking the tablets, a withdrawal bleeding event is expected to occur. Official product information states this bleeding typically resembles a normal menstrual period and usually starts within 2 to 4 days of discontinuing the medication.


Q: How long after stopping Primosiston Tablets will my period return?

Following the expected withdrawal bleed, the return to your usual, regular menstrual cycle patterns may take time as the body adjusts. Regulatory information on similar hormonal agents suggests that normal ovulation and regular cycles usually return within a period ranging from a few weeks up to three months.


Q: Is it common to feel tired or dizzy after starting Primosiston Tablets?

While these effects may not be classified as common, certain regulatory documents list dizziness and somnolence (drowsiness or fatigue) as possible adverse effects associated with the use of the active ingredient. As with any medication, patient responses can vary.


Q: Can I take pain relievers like ibuprofen with Primosiston Tablets?

Regulatory data regarding drug interactions for the active ingredients confirm that no formal interaction has been documented with the common pain reliever ibuprofen. This suggests that the combined use is not a prohibited interaction. All medications should be discussed with a healthcare provider before combination use.


Q: Can using Primosiston Tablets affect hair growth or skin conditions?

Regulatory warnings include a specific caution regarding chloasma, which appears as dark patches on the skin, particularly for individuals with a history of the condition. It is noted in official documentation that patients should avoid sun exposure when taking this medication.


Q: Does Primosiston Tablets help with menstrual cramps (dysmenorrhea)?

Regulatory documents describe the active ingredient's application in conditions like functional dysmenorrhoea (menstrual cramps). The official documentation notes that the suppression of ovulation by the medication can be associated with the relief of these symptoms.


Q: Is it known if Primosiston Tablets passes into breast milk?

Use of this medicine during lactation (breastfeeding) is strictly prohibited and is listed as an absolute contraindication in the regulatory information. This is because the active ingredients are known to pass into breast milk, and the combination product is considered unsuitable for use during this period.


Q: What are the signs that Primosiston Tablets is not working as expected?

Regulatory documents state that if the expected uterine bleeding does not stop after taking the tablets correctly, or if heavy bleeding reappears after an initial halt, this could be a sign that the medication is not working as expected. In such cases, official documents indicate that medical consultation is warranted to rule out other possible underlying issues.


Q: Are there warnings about driving or operating machinery while on Primosiston Tablets?

Yes, regulatory warnings advise that adverse effects of this type of medication may potentially affect a person's ability to drive or operate machinery safely. Specifically, effects such as dizziness and visual disturbances are listed in the official safety profile.


Q: Can Primosiston Tablets cause changes in vision?

Regulatory documentation lists abnormal vision and visual disturbances as possible adverse effects associated with the medication. It is also noted that the most serious ophthalmologic complications are associated with rare thromboembolic events, such as retinal artery occlusion, which is a serious safety concern.


Q: Is it normal to have a very heavy period after stopping Primosiston Tablets?

The expected outcome after stopping the tablets is a withdrawal bleeding event that resembles normal menstruation in intensity and duration. If a very heavy period occurs, regulatory documents indicate that medical consultation is warranted, as it may suggest the return of underlying heavy bleeding issues.


Q: Do people with liver issues need special consideration when using Primosiston Tablets?

Yes, the use of this medicine is prohibited for individuals with severe liver disease or liver tumors. Additionally, the regulatory profile notes that high doses of progestins can be associated with elevations in liver enzymes and other liver test abnormalities, warranting caution.

How should Primosiston Tablets be stored and disposed of?

The official regulatory profile for Primosiston tablets outlines specific storage and disposal requirements to ensure product integrity and safety.

Storage Requirements

Primosiston tablets must be stored at a temperature not exceeding 30 C (86 F). To maintain the product's stability and shelf-life, the medication must be kept in the original container and packaging to protect it from both light and moisture. As with all medicines, the tablets must be stored out of the sight and reach of children.

Disposal Instructions

Disposal of unused or expired Primosiston tablets must be executed in accordance with local requirements for pharmaceutical waste. The product should not be disposed of via wastewater or household refuse to prevent environmental contamination, necessitating use of authorized drug take-back programs.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Primosiston Tablets found in:

A-Z Index: